REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 133 filers reported holding REATA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $14,682 | +11.4% | 144 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $13,183 | +339.3% | 145 | +83.5% | 0.00% | – |
| Q4 2022 | $3,001 | +50.0% | 79 | +8.2% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 73 | +49.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 49 | +96.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 25 | -3.8% | 0.00% | -100.0% |
| Q3 2021 | $3,000 | -25.0% | 26 | -16.1% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | -20.0% | 31 | -36.7% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 49 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,000 | +200.0% | 49 | +145.0% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | -93.8% | 20 | -95.0% | 0.00% | -91.7% |
| Q3 2019 | $32,000 | – | 400 | – | 0.01% | – |
| Q2 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2019 | $42,000 | 0.0% | 500 | -33.3% | 0.02% | -19.0% |
| Q4 2018 | $42,000 | – | 750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
| Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
| MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
| Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
| Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
| Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
| Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
| Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |